Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.66 |
| ▸ | MEN1 | O00255 | 4/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.66 |
| ▸ | NPC1 | O15118 | 3/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.62 |
| ▸ | MAPT | P10636 | 5/20 | 0.62 |
| ▸ | RAB9A | P51151 | 3/20 | 0.62 |
| ▸ | LMNA | P02545 | 3/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.62 |
| ▸ | HTT | P42858 | 2/20 | 0.62 |
| ▸ | PARP1 | P09874 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17236166 | 0.88 | SMN1; SMN2 (0.77) | SMN1; SMN2KMT2AMEN1CYP1A2CYP2C19 | |
| SCHEMBL4652925 | 0.82 | SMN1; SMN2 (0.71) | SMN1; SMN2KMT2AMEN1CYP1A2CYP2C19 | |
| SCHEMBL18706992 | 0.81 | SMN1; SMN2 (0.68) | SMN1; SMN2KMT2AMEN1CYP1A2CYP2C19 | |
| SCHEMBL14019207 | 0.80 | SMN1; SMN2 (0.67) | SMN1; SMN2KMT2AMEN1NPC1ALDH1A1 | |
| SCHEMBL7377540 | 0.79 | SMN1; SMN2 (0.67) | SMN1; SMN2KMT2AMEN1CYP1A2CYP2C19 | |
| SCHEMBL17087710 | 0.79 | NPC1 (0.75) | SMN1; SMN2KMT2AMEN1CYP1A2CYP2C19 | |
| SCHEMBL28432111 | 0.78 | KMT2A (0.72) | SMN1; SMN2KMT2AMEN1CYP1A2CYP2C19 | |
| SCHEMBL37273 | 0.78 | ALDH1A1 (0.68) | SMN1; SMN2KMT2AMEN1NPC1ALDH1A1 | |
| SCHEMBL10282875 | 0.78 | SMN1; SMN2 (0.63) | SMN1; SMN2KMT2AMEN1CYP1A2CYP2C19 | |
| SCHEMBL401199 | 0.77 | L3MBTL1 (0.64) | SMN1; SMN2KMT2AMEN1CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10252984-B2 | Inhibiting G protein coupled receptor 6 kinase polypeptides | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2019-04-09 | — | — | US | disclosed |
| US-20140309185-A1 | Inhibiting G Protein Coupled Receptor 6 Kinase Polypeptides | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2014-10-16 | — | — | US | disclosed |
| US-20140309185-A1 | Inhibiting G Protein Coupled Receptor 6 Kinase Polypeptides | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2014-10-16 | — | — | US | disclosed |
| WO-2013063458-A2 | INHIBITING G PROTEIN COUPLED RECEPTOR 6 KINASE POLYPEPTIDES | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2013-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140309185-A1 | Inhibiting G Protein Coupled Receptor 6 Kinase Polypeptides | GRK6, GRK2, GRK3 | SMN1; SMN2 4298/4885KMT2A 3122/4885MEN1 2721/4885 |
| US-10252984-B2 | Inhibiting G protein coupled receptor 6 kinase polypeptides | GRK6, GRK2, GRK3 | SMN1; SMN2 4298/4885KMT2A 3122/4885MEN1 2721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.